CD4 and inflammatory bowel disease: These LPAM1+ (α4β7 integrin) CD4+ T cells are critical for the initiation and development of inflammatory bowel disease (IBD) (80, 81) and are being targeted by monoclonal antibodies etrolizumab (β7) and natalizumab (α4).